BRCA2 mutations and triple-negative breast cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Meyer, Peter ^a   Landgraf, Katharina ^a   Högel, Bernhard ^b   Eiermann, Wolfgang ^c   Ataseven, Beyhan ^c  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b Red Cross Hospital   (Germany)

^c Frauenklinik vom Roten Kreuz   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; ISOLEUCINE; METHIONINE; THREONINE; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRCA2 GENE; FAMILY HISTORY; GENE MUTATION; GENOTYPE; GERMANY; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; ONCOGENE; OVARY CANCER; POINT MUTATION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; COHORT ANALYSIS; FEMALE; GENETICS; GENOTYPING TECHNIQUE; MALE; METABOLISM; MIDDLE AGED; MUTATION RATE; NUCLEOTIDE SEQUENCE;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; MUTATION RATE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84861603883     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038361     Document Type: Article

References (17)

1. Foulkes WD, Smith IE, Reis-Filho JS, (2010) Triple-negative breast cancer. 20 N. Engl. J. Med 363 pp. 1938-1948.
2. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS et al, (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9: 86.
3. Evans DG, Howell A, Ward D, Lalloo F, Jones JL et al, (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. 8 J. Med. Genet 48 pp. 520-522.
4. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK et al, (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. 5 Clin. Cancer Res 17 pp. 1082-1089.
5. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K et al, (2011) Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. 1 Breast Cancer Res. Treat 129 pp. 185-190.
6. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC et al, (2007) American Society of Clinical Oncology/College of Ameri-can Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. 1 J. Clin. Oncol 25 pp. 118-145.
7. Meyer P, Voigtlaender T, Bartram CR, Klaes R, (2003) Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovar-ian cancer families in Southern Germany. 3 Hum. Mutat 22.
8. kConFab Classification of BRCA1 and BRCA2 Mutations. Available:http://www.kconfab.org/Progress/Classification.shtml.
9. Bauerfeind I, (2011) Mammakarzinome. In: Diagnostik Empfehlungenzur, editors. Therapie und Nachsorge] München [i.e.] Germering [u.a.] Zuckschwerdt. XII, 340 S.
10. Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I et al, (2011) Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. 2 J Community Genet 2 pp. 53-69.
11. Antoniou AC, Pharoah PDP, Narod S, Risch HA, Eyfjord JE et al, (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. 7 J. Med. Genet 42 pp. 602-603.
12. Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L et al, (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. 23 J. Natl. Cancer Inst 98 pp. 1694-1706.
13. Borg A, Haile RW, Malone KE, Capanu M, Diep A et al, (2010) Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. 3 Hum. Mutat 31 pp. E1200-40.
14. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D et al, (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). 1 Cancer Epidemiol. Bio-markers Prev 21 pp. 134-147.
15. Rajasekaran R, Sudandiradoss C, Doss CGP, Sethumadhavan R, (2007) Identification and in silico analysis of functional SNPs of the BRCA1 gene. 4 Genomics 90 pp. 447-452.
16. Krupa R, Sliwinski T, Morawiec Z, Pawlowska E, Zadrozny M et al, (2009) Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer. 4 Exp. Oncol 31 pp. 250-251.
17. National Comprehensive Cancer Network, (2011) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Available:http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.